Q2 2023 Better Therapeutics Inc Earnings Call
Hello, and thank you for standing by and welcome to the better Therapeutics second quarter 2023 update call. At this time all participants are in a listen only mode. After the speaker presentation there'll be a question and answers session.
To ask a question during the session you will need to press star one one on your telephone you wouldn't hear an automated message advising your hand is race.
Please be advised that today's conference is being recorded.
I'd now like to hand, the conference over to your Speaker today, Marc Heiden, Chief Financial Officer. Please.
Yeah.
Thank you operator.
Good afternoon, everyone and welcome to the better Therapeutics Conference call. Our press release was issued this afternoon and can be found in the investors section of our corporate website, better TX Dot com.
Joining me on the call today is Frank carbon our President and Chief Executive Officer, Dr. Marc Berman, our Chief Medical Officer, and I haven't got my status our.
Our chief commercial officer.
During today's call, we will provide a business update.
Nigel overview of the second quarter of 2023 acute.
The Q&A session will follow our prepared remarks.
Before we begin I'd like to remind everyone that any statements, we make or information presented on this call that are not historical facts are forward looking statements that are based on our current beliefs plans and expectations and are.
Made pursuant to the Safe Harbor provisions of the private Securities Litigation Reform Act of 1995.
Actual events or results may differ materially from those expressed or implied by any forward looking statements.
With that I'll pass the call over to Frank Harbor Frank.
Thank you Mark and good afternoon, everyone. Thanks for joining us on the call today.
I will begin with a brief recap of the exciting news we shared recently regarding FTA authorization.
In July Aspire Rx, formerly known as B T 001 received FDA authorization as a class II medical device indicated to treat adults with type two diabetes.
This marks the culmination of eight years of development involving more than 6000 participants and studies of increasing rigor.
And with this FDA authorization, a new regulatory class of digital Therapeutics has been established with aspire Rx being that first prescription only digital therapeutic treatment to provide cognitive behavioral therapy or CBT two adult patients with type two diabetes.
It's by our excess based on our proprietary form of CBT developed by better therapeutics, specifically for treating cardio metabolic diseases and designed to overcome many of the limitations of traditional in person CBT.
Aspire exports granted marketing authorization based on efficacy and safety data from our randomized controlled trial involving 668 participants demonstrating clinically meaningful and statistically significant reduction in HBA, one C as well as improvements in other health outcome measures, which were <unk>.
In peer reviewed journals and presented at various conferences.
As a prescription digital therapeutic aspire Rx is differentiated from general health apps due to its rigorous clinical testing.
FTA authorization as a class II medical device.
And its indication for treatment, rather than just monitoring and data tracking.
It requires a health care providers prescription and it's designed to be integrated into patients overall care management.
Ensuring expert oversight and coordination.
Additionally, despite rx adheres to strict security and data privacy standards to protect patient information and medical devices from cyber threats.
FTA authorization of a spy Rx is significant on multiple levels.
It is an important advancement in the diabetes treatment landscape.
Providing clinicians with a standardized evidenced based and prescriber will form of CVT to empower patients and making sustainable behavior changes.
It facilitates the implementation of current type two diabetes treatment guidelines.
And lowest access to care hurdles as it can be used by any patient with a smartphone.
The establishment of a new class of FDA authorized devices to treat diabetes with CVT also opens possibilities for future expansion into related cardio metabolic diseases.
And lastly, the authorization has broadened our business development discussions.
Yeah.
I'll now recap other accomplishments in the second quarter and July of this year.
We've advanced our preparations for the commercialization of inspire Rx.
Including the completion of the quantitative pricing study and a decision on price.
We've also made significant progress in our launch readiness efforts with Phil.
Honestly in hub partner.
Furthermore, FDA authorization has accelerated conversations with payers and we are encouraged by the meetings we're having.
The awareness of PDT.
<unk> to grow amongst payers.
In part because there are now over 10 pdt's on the market and in part because of the ongoing efforts to provide coverage for Medicare and Medicaid patients.
For example in June the Academy of managed care Pharmacy sponsored event in Washington D. C to advocate for the access to prescription digital Therapeutics Act a policy priority for them.
This followed our own recent advocacy efforts in which we participated alongside other members of the digital Therapeutics Alliance to advocate for the Bill, which if passed would provide a Medicare benefit category for prescription digital therapeutics and which facilitate.
Coverage familiars of patients.
We further strengthened our financial position by completing multiple financings throughout the second quarter and into July .
Raising $12 $5 million in net proceeds.
We tend to use the proceeds to support the commercial launch of aspire Rx in Q4 of this year.
Yeah.
We're pleased to report we have enrolled approximately 90% of the target participants and our real World evidence studies and are on track to complete enrollment by the end of Q3 of this year.
And lastly, our abstract describing a less feeder study results was presented at the European Association for the study of the liver or <unk> annual Congress.
<unk> is a leading professional society and their clinical practice guidelines and from the standard of care for naphthalene Nash around the world.
We have delivered on multiple critical milestones through the first half of this year.
There are exciting opportunities ahead of us.
The commercial potential for aspire Rx is significant.
We continue to get very encouraging feedback from providers Payors and patients.
And we're exploring multiple business development and royalty options to get our product to as many patients as possible as quickly as possible.
I will now hand, it over to Diane to share more detail around the commercial strategy Diane.
Thanks, Frank This is exciting progress I will start with a payer update.
Immediately upon the announcement of SBA authorization for aspire Rx, we shared this milestone with payers on our target list and have completed six post authorization meeting with key senior decision makers to review our label and review the clinical data in more detail.
Several of these have now advanced to follow on conversations with broader team members at these payer organization and additional meetings have been scheduled for the coming week. We are encouraged by payers willingness to meet with us. So quickly after the FCA authorization and feedback has been encouraging as payers recognize the unmet needs that exist.
In type two diabetes and are looking for ways to control the escalating costs associated with this patient population.
We continue to get positive reactions from them.
Weighted to our trial design that is it is very drug like with a clinical endpoint of <unk> reduction. It is inclusive of a diverse type two diabetes population and the fact that it is a sizable randomized control trial, we are finalizing our National Association of managed care physicians or.
N a N C P dossier, which we will use to facilitate even broader communication about aspire Rx to payers.
I will now move onto price, which is a key factor for payer economic and coverage analysis. After just completing our latest pricing research, we decided to set the wholesale acquisition cost or list price for inspire Rx for a 90 day treatment at $750 we Ain't.
Dissipate most patients will get at least one retail for a minimum treatment period of six months.
Unlike many drugs that are meant to be used indefinitely aspire Rx has a predefined duration.
At $1500 per patient for a six month treatment experience. We believe is well priced when considering the costs associated with chronic medications. We are confident we provide a compelling value proposition to payers offering cost predictability for a defined period of time. Unlike other treatments.
In the most recent quantitative pricing research, which include a pharmacy director medical directors and Pbms director payers view aspire Rx favorably with greater than 72% of payers finding via our valuable and 64% of payers anticipating covering it and this is consist of.
With prior studies and payer meeting, both pre and post authorization.
We are acutely aware of the challenges that people with diabetes space due to out of pocket costs associated with managing their condition and our commitment to ensuring the broad access to aspire RF at an affordable price has been central to our mission at better therapeutics to.
To achieve this we've been actively working to get aspire Rx covered by insurance plan and aim to reduce the financial burden on people with diabetes, while enabling them to access the high quality care they deserve.
And our list price was set with this in mind.
We know that we won't have broad insurance coverage at launch. However, it is vitally important that we provide patients and providers a good experience through our distribution pharmacy partner claims will be processed to demonstrate demand for payers for.
For patients who may have claims rejected by ensuring we will offer for a limited time it reasonably priced cash pay option with a focus of maintaining low patient out of pocket costs.
We expect this to yield several benefits, including doctors gaming experience and confidence in prescribing aspire RF patients being able to access the treatment and better therapeutics generating initial revenue.
Moving to our go to market update we are pleased by the broad label, enabling us to offer aspire Rx to the vast majority of the currently diagnosed 29 million adults living with type two diabetes in the U S.
As previously outlined our initial focus is to reach the patients considered most urgent by payers and providers, who are not yet at a <unk> target roughly 14 million people.
We have identified these patients and their prescribers and health system affiliations.
Together with our target list of innovative regionally dominant payers', our analyses point plus two 5% to six priority geographies for initial focus and where we can sequence in sales personnel and health system account leads as we gain traction.
And with virtual resources, we built in flexibility to support any prescribing Doctor who is an early adopter.
With regards to the VA, we are working diligently to provide access for spire Rx finalizing our Sam registration the system for award management, which is a government wide registry for vendors doing business with the federal government registration is followed by negotiation for access via the <unk>.
All supply schedule, we plan to have dedicated resources to drive awareness and penetration of aspire Rx in the VA.
And as mentioned previously the Durham VA site as part of our ongoing clinical study program.
Dedicated to providing veterans access to this innovation.
To further inform our initial provider level targeting we just completed a segmentation study that has identified innovative providers, who show high interest and willingness to prescribe expire are very quickly upon commercial release of the product. This group is comprised of approximately <unk> <unk>.
<unk> 1100 providers from the top two decile of providers not from our patient claims analysis, 74% of whom are endocrinologists and diabetologist with a high volume of patients on average they have seen over 500 patients with type two diabetes in the last six months and are actively using diabetes.
Technology in their practice.
61% of this group is already familiar with digital therapeutics and on average have recommended various app based solutions 38 times in the last month. Our goal is to ensure aspire RF becomes the preferred digital treatment to prescribe.
These providers indicate that on average they would prescribe aspire rx to half of their patients.
Top drivers for these tech savvy providers, our patient engagement in the app ease of use and low out of pocket costs.
Given aspire Rx is strong patient engagement data from the pivotal trial with 81% of patients still engaging with treatment at six months combined with our plans for gaining payer coverage and an affordable cash pay option. We are eager to connect with this targeted group of HCP.
There is another equally large group of early adopters, who are just as aware of digital therapeutics and are also likely to prescribe aspire Rx to almost half of their patients provided coverage is in place.
As we have shared previously there is a lot we have learned from prior PDP launches and in the first two quarters. After launch we will be closely monitoring and reporting on the following leading indicators.
Number of prescriptions, both scripts and rebuilt the number of health care providers, who are prescribing aspire Rx, both new prescribers and repeat prescribers.
Payer coverage, both the number of lives covered and the percent of prescriptions that are reimbursed.
In summary, we are at a pivotal juncture in our journey of better therapeutics as we transform into a commercial organization with FDA authorization coming through last month as planned we are standing up a number of critical functions, including our commercial infrastructure build activating recruitment for our field team at.
Advancing commercial strategies, such as the cash pay program and continuing to engage with payers across the country I'm enthusiastic and confident in the potential we have with aspire Rx.
Mark Hyman, our Chief Financial Officer will now review, our second quarter 2023 financial results Mark.
Thank you Diane.
I will start by discussing our operating expenses for the second quarter of 2023.
R&D expenses were $2 2 billion for the quarter compared to $4 2 million for the same period in 2022.
The decrease was primarily due to a $1 million decline in clinical study costs as we completed the pivotal trial last year and a 700000 decline in personnel related costs as a result of savings for the restructuring in the first quarter of 2023.
Sales and marketing expenses were $1 7 billion, which was flat year over year.
Personnel related costs increased 300000, as we continue to advance our preparations for commercial launch of aspire Rx.
This was offset by a 300000 and severance charge in the second quarter of last year.
G&A expense for the quarter were $3 1 million compared to $3 7 million for.
For the same period in 2022.
The decrease was primarily related to lower business insurance costs.
Interest expense for the quarter was 600000 compared to 300000 for the same period last year. The increase was primarily the result of higher interest rates and an additional 5 million borrowed under the company's secured term loan agreement in the second quarter of last year.
Net loss was $7 6 million compared to $9 9 million in Q2 last year.
On a per share basis net loss was 24 cents for the quarter compared to <unk> 41 last year.
The decline in loss per share is related to lower net loss as a result of savings from our restructuring in the first quarter of 2023, and an increase in weighted average shares outstanding.
Moving to our balance sheet cash and cash equivalents were $6 2 million on June 32023, compared to $15 7 million on December 31 2022.
In July 2023, we completed equity financing for gross proceeds of $6 7 million.
So on a pro forma basis, taking into account the financings cash and cash equivalents was $12 9 million at the end of the second quarter.
Our cash burn in the second quarter was $6 million and declining from Q1, primarily as a result of the restructuring and other cost savings initiatives.
The lower cash burn and the recent equity financing are expected to extend our cash runway toward the end of Q4 allowed us to potentially be several key milestones, including commercial launch.
I will now hand back over to Frank for some closing remarks.
Thank you Mark.
Before we wrap up I want to address where we stand in the evolution of better therapeutics overall.
Now there are three key areas, we've been focused on de risking over the past few months.
The FDA authorization of a spy Rx with a favorable label resolve the regulatory risk and has cleared the way for commercial launch.
We now need to demonstrate commercial traction.
To do that we need adoption from providers Payors and patients.
And we believe we're in a good position to achieve this.
We have a great product as demonstrated by the strong results of our pivotal trial.
We continue to receive positive feedback from providers.
And our approach to treating type two diabetes through behavior change is already included in the treatment guidelines.
Furthermore, the encouraging feedback from payers the <unk>.
Findings from our payer research and the quickly evolving landscape of PDT in general give us.
Confidence payer coverage will be successfully obtained.
However, because pdt's are still a relatively new category obtaining broad coverage will take some time.
As Diane shared our research suggests that there's a sufficiently large number of providers that are likely to be early prescribers of aspire Rx to give us meaningful commercial traction and feedback from patients to date suggests that being honest by Rx can be life changing.
To ensure providers and patients have a good experience with us by Rx at the outset.
And while we are building coverage the cash pay option, Diane mentioned will be priced appropriately to enable broad patient access.
We believe this will not only drive early provider and patient adoption, but also accelerated our efforts to broaden payer coverage.
It is coverage broadens, we expect an increasing number of scripts to switch from cash pay to cover scripts, which in turn will drive our revenue.
So this is broadly how we expect the dynamics of our launch to play out.
Yeah.
In parallel we need to ensure we have adequate financial resources.
The latest financings, we have extended our cash runway through the end of the year, allowing us to potentially meet multiple important milestones and secure further funding.
We're focused on the following key milestones for the remainder of the year.
With regards to the commercial launch of Aspire Rx, we expect to make aspire X commercially available in Q4 of this year ideally we announced initial payer coverage around the same time and continue to broaden coverage before the end of the year along with getting on the federal supply schedule.
Second completing enrollment in <unk>, one railroad evidenced programs, we expect to complete enrollment by the end of the third quarter and pending sufficient power, we expect to share. The first data set from these long term effectiveness studies in the fourth quarter of this year.
Third.
Request breakthrough device designation following the successful completion of the live Vita liver study, we intend to submit a request to the FDA for breakthrough device designation for non alcoholic fatty liver disease natural food and non alcoholic <unk> hepatitis or Nash by the end of 2020.
Three.
And fourth.
Further strengthened our financial position, we expect to complete a business development partnership was structured financing transaction such as the royalty monetization before the end of the year.
In closing, we envision aspire Rx, becoming part of the standard of care for most adults living with type two diabetes.
It's a unique combination of aspire access mechanism of action.
Safety and efficacy profile broad utility and accessibility and potential health economic benefits truly set it apart and positioning it to succeed.
Yes.
And with that we're now ready to take your questions. Thank you.
As a reminder to ask a question. Please press star one one on your telephone and wait for your name to be announced to withdraw. Your question. Please press star one again please.
Please standby, while we compile the Q&A roster.
Our first question comes from Charles <unk> with T. D. Cohen Your line is open.
Hi, This is Lucas on FERC Charles.
Wanted to ask I understand it's obviously early days here and we haven't launched but.
Wanted to see if you guys can point us directionally to what Opex could look like.
Once we hit the commercialization.
And then also what.
If you guys have any.
Sales projections for the first year of commercial launch.
Hey, Lucas.
Thanks for your question and good afternoon.
So regarding your.
Operating expense question I think as you know we have.
Substantially curtailed our operating expense in the early part of this year through a restructuring.
And.
Through the early innings of the launch.
We expect our operating expense to remain roughly flat maybe increased slightly.
And the goal here is to first demonstrate.
Early commercial traction before we expand our operating expense beyond the current levels in a meaningful way. We think that is the most prudent approach to take and.
That's the path that we're going to pursue so you can expect over the next let's say at least two quarters or operating expense too.
Not change in any significant way.
And then it really depends how.
Commercial traction evolves and of course, if we if we see good commercial traction. We would then want to expand our commercial footprint and with that you would then see a commensurate increase in expense with regards to your second question about.
Revenue, we are not providing revenue guidance at this point I think generally.
It is wise to wait until we have at least two to three quarters of launch experience under our belt and we have a better understanding of the launch dynamics.
Okay.
Thanks understood.
And then I guess, a question around Nash and novelty.
<unk> of going to the markets.
Pending receiving breakthrough designation would there be any changes to make to your commercial strategy for diabetes or will you be able to plug and play into the same targeted payer and physician population.
Just trying to think.
About that dynamic.
Yes, so there's actually several points to make here. The first one relates to the product itself, where you haven't really asked about this but I want to address it nevertheless, because it's one of the unique aspects of <unk>.
Office by Rx and the platform that we've built in that the underlying behaviors that are <unk>.
Driving the progression of type two diabetes are largely the same that are driving the progression of Nash naphtha naphtha and other cardio metabolic diseases and so we believe we can use the platform with very modest modifications to easily be then applied to.
Two other cardio metabolic indications.
So that's point number one the second point with regards to.
What type of providers.
Target it depends a little bit from.
From indication to indication, but we would expect there to be a large overlap.
To the.
To the providers that we're targeting with our type two diabetes launch.
Okay.
Okay, great. Thanks.
One moment for our next question.
Our next question comes from Thomas Flaten with Lake Street Capital markets. Your line is open.
Hey, good afternoon, everyone. I appreciate you taking the questions Frank for the real World evidence study how many patients will you have enrolled assuming the powering is still there or that you will report out on.
Yes, Hi, Alex Thanks for your question I'll actually let our.
Mark.
Berman answer that question.
Hey, Thomas Good afternoon. So the study is going to enroll approximately 1000 patients.
And our estimates would point roughly around half of those having interim data.
By the end of the year, but as mentioned you know we're going to be taking a look at the power for the results that we have to make sure that we're adequately powered before releasing results you wouldn't want to be.
Premature about releasing results that we didn't think were.
Likely to be representing the final sample.
Excellent. Thank you I'm not sure if youre willing to share what your cash pay price will be but I'm. Just curious if you could at least share.
What comparables you used to come up with what you think is.
Reasonable price for sure out of pocket.
Yeah. So.
I think you've picked up and in fact, we have not yet finalized the decision on the cash pay price.
But our objective is to price it at a level that will minimize patient drop off and maximize adoption and I can tell you from the latest pricing research that we have done when when asked directly on price and out of pocket costs for patients providers indicate a range of 25 to $50 per month.
As a reasonable Max out of pocket expense for patients and win win when asked patients directly they indicate a range of 40 to $55 per month.
As a reasonable a max price range for out of pocket costs. So it is going to be somewhere in that vicinity because that is what I think the latest market research indicates to be.
The sweet spot and to achieve our objective of maximizing adoption.
Got it and Diane from your comments.
You mentioned, 5% to six geographies that you're targeting but also 1100 providers I was curious if I should read five to six geographies.
Five to six reps, which makes that seemed like a pretty heavy.
<unk> burden for those trucks to Kerry I was wondering if you could help me reconcile those two numbers.
Hey, Thomas it's nice to hear from you.
So with regards to the five to six geographies, we've been able to identify these priority geographies based on several datasets and input which include our patient claims analyses the associate of prescribing physicians and their connection to health system health system profiles as well as the analysis that we've conducted.
With regards to regionally dominant payor that overlap with the large health system. When we went about conducting our segmentation data our segmentation study it's important to note that the.
Health care providers.
Were sourced from the patient claims analysis and mapping.
The top tier decile and from those.
Cohorts of physicians, we were able to identify these early innovators are 1100. These do span to be cleared nation wide.
And so as you can understand certainly a small clean.
That is a burden and so for us we're looking at maintaining flexibility depending on how our momentum ramps as we released the product into markets and so our team. We're estimating a about 10 will includes sales payer lead.
Medical science liaisons as well as VA specialists and for US we will be focused on where we have that early.
Adoption from from both provider levels at the health system level, and where we're able to access coverage. Early so we are really focused on being extremely flexible and as I had previously stated the health system approach is one that allows for efficiency. If we can get to these early adopters who tend to be.
Be endocrinologists, who are influencers within the health system, we expect to have a <unk>.
Faster and broader reach with that approach.
Got it and then one I know I've asked you before but any any stronger sense today on <unk>.
Whether this will ultimately funnel into pharmacy versus medical benefit.
It's a good question and even.
Through our most recent conversations post announcements and authorization of aspire Rx, we still get mixed feedback from payers and I'll just emphasize that we do have a partner here with Taylor online pharmacy that allows for optionality, whether payers choose to cover via pharmacy.
Benefit or medical benefit.
Got it I appreciate you taking the questions. Thank you.
Thanks, Tom.
One moment for our next question.
Our next question comes from Kian Mackay with Chardan. Your line is open.
Yes. Thank you.
I'm wondering if you can give us some qualitative.
Sort of how the early discussions with payers are going post the authorization.
I guess, maybe specifically as it might pertain to value based pricing agreements.
Nike Nice too nice to have you on the call and thanks for your question, Yes, we can comment on that a little bit I will hand, it over to Diana just a second just as an intro remarks, we have actually been quite encouraged by the latest round of discussions that we've had since the announcement of FCA authorization clearly once we <unk>.
FDA authorization that acted as a catalyst.
For accelerating and broadening our payer discussions and.
The feedback that we've gotten so far.
As encouraging Dan maybe you want to comment a bit more on what we've heard yes. Thanks. Thanks Frank.
We'll say that we are very encouraged by these multiple post authorization meetings that have taken place. This announcement, we are getting to the senior decision makers, which I'm really happy to see their interest while we've also advanced conversations.
With other regional payers Pbms and national payers were showing interest and inspired Rx beyond our targeted lift the meetings are very focused on reviewing our updated label as we mentioned during our announcement call. We're very happy to have the broad label and to be able to share that with with payers has been important and we are reviewing in more depth.
Our clinical data.
And this is now leading on to follow on conversations with broader team members at these payer organizations and consistent with what we've heard even pre authorization. The positives really are around our trial size. The fact that we have very compelling and clinically meaningful endpoints of our study the diversity of our.
Our population the sizable.
And also.
The fact that.
There is an acknowledgment that we see some reduction in medications for the intervention arm in our study. So all of that is very compelling you asked specifically to the value based agreements. These certainly do come up in our conversations and as a reminder, we conducted research earlier this year to understand the role Vba's Mike.
Play and coverage discussions and we do know that they will be important for some of these payer negotiations and as we move on to these in a secondary meetings with the broader team members at the payer organizations I'm sure that we will engage in more detail around these ppas.
Which will likely be structured around engagement metrics or clinical outcomes as consistent with the research we did earlier this year.
And is it is it fair to assume.
Go down the path of what the EPA with the payer.
So they're more interested in and the durability that might lead to more.
Six month prescriptions.
For sure one of the outstanding question that continues.
To come up in conversations with payers is the durability of response beyond six months, what I can say is that throughout all of our conversations pre and post our expectation is that as <unk>.
<unk> will likely.
B a treatment to have both and index and a refill.
90 day script and beyond that you know there there was a question of the durability and that's where our current real world evidence program, we'll be able to provide some more insight into that but at this point that isn't outstanding questions and vba's for sure these value based agreements or an opportunity to.
Addressed this question with Payors.
Okay great.
Yes.
Just add there are a number of different variables beyond what you just mentioned that are important to to.
To payers, we've talked about some of them in the past and one of them that we are encouraged by actually is engagement.
Which is something that we believe we can manage quite well.
And we've gotten good feedback on that from <unk>.
From payers.
Yeah.
Okay. Thank you.
One moment for our next question.
Our next question comes from Rahul rocket with lifestyle capital. Your line is open.
Okay.
Hey, guys. Thanks for taking the question.
Diana you mentioned.
Just like a 100.
Early prescribers that said that.
I think roughly 40% of our patients likely.
Prescribed as to was there any follow up.
The profile or characteristics.
All of those.
Cohort of patients.
Yes is there any sense of.
Who or what patient profile these docs.
<unk>.
Ideal for the PD too early on that.
Yes, Hey, Rahul nice nice to hear from you.
Yes, we were very encouraged with this data keeping in mind that this research.
With a quantitative studies so did not have the opportunity to engage in deep conversations with this cohort, but what I can tell you is that the top drivers for prescribing to be patients include.
Patient engagement ease of use and low out of pocket. So specific to this innovator group with patient engagement comes up and its ease of use and so they really are looking at patients who are likely familiar with technologies and are able to use app per day, but there is no.
Additional color from the some quantitative study in detail there.
Got it.
And I appreciate you guys kind of talked.
Top two drivers there.
We were also able to identify any potential barriers that lead to some potential hesitation. Among prescribers that you guys see an opportunity to further educate.
Prescribers and kind of drive.
Adoption early on.
Yeah, I actually with the <unk>.
<unk> by by the group and specific to this innovator group a barrier would be for example, lack of insurance.
Or if it appears complicated for patients.
It'd be good for less tech savvy patients and that's specific to this.
Innovator group that that I've highlighted in so obviously insurance comes up here, but also again the ease of use and so they are thinking about their patients and who would be more or less tech savvy.
Got it that's helpful. Thanks for taking the questions.
Okay.
This concludes today's conference call. Thank you for participating you may all disconnect.
Okay.
Okay.
[music].
Okay.
[music].